Peptide Initiative

Peptides · Peptide comparison

Cathelicidin (hCAP-18 / Synthetic Derivatives) vs Thymalin

Human cationic antimicrobial protein-18 (hCAP-18) precursor and its synthetic derivative SAAP-148 — a next-generation 24-amino-acid cathelicidin-based peptide with broad-spectrum bactericidal activity against multidrug-resistant ESKAPE pathogens including MRSA biofilms, superior potency to its parent fragment LL-37, and retained efficacy under physiological salt and plasma conditions

Russian thymic peptide complex that rejuvenates immune function and supports healthy aging

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeCathelicidin (hCAP-18 / Synthetic Derivatives)0.5–0.5 mg/mLThymalin5–10 mg
FrequencyCathelicidin (hCAP-18 / Synthetic Derivatives)Once dailyThymalinOnce daily
AdministrationCathelicidin (hCAP-18 / Synthetic Derivatives)Topical application (primary research route)ThymalinIntramuscular injection
Cycle lengthCathelicidin (hCAP-18 / Synthetic Derivatives)4-6 weeksThymalin4-6 weeks
Onset speedCathelicidin (hCAP-18 / Synthetic Derivatives)Rapid (hours to days)ThymalinModerate (1-2 weeks)
Evidence levelCathelicidin (hCAP-18 / Synthetic Derivatives)Moderate human trials (Phase 1-2)ThymalinLimited human trials

Efficacy

Benefit ratings

Antibiotic-Resistant Infections

Cathelicidin (hCAP-18 / Synthetic Derivatives)72%
ThymalinNo recorded rating

Biofilm Destruction

Cathelicidin (hCAP-18 / Synthetic Derivatives)68%
ThymalinNo recorded rating

Immune System Support

Cathelicidin (hCAP-18 / Synthetic Derivatives)58%
ThymalinNo recorded rating

Immune Restoration

Cathelicidin (hCAP-18 / Synthetic Derivatives)No recorded rating
Thymalin88%

Longevity Support

Cathelicidin (hCAP-18 / Synthetic Derivatives)No recorded rating
Thymalin82%

Disease Prevention

Cathelicidin (hCAP-18 / Synthetic Derivatives)No recorded rating
Thymalin78%

Technical data

Compound specifications

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Molecular formula
hCAP-18: ~18 kDa precursor protein (170 AA); SAAP-148: C155H253N49O31 (approximate), MW 3,267.1 Da
Molecular weight
hCAP-18 precursor: ~18,000 Da; SAAP-148: 3,267.1 Da; OP-145: ~2,900 Da
Half-life
Plasma half-life: minutes (proteolytic degradation); local tissue persistence: hours at therapeutic concentrations in wound environment; enhanced stability compared to LL-37 due to N-terminal acetylation and C-terminal amidation
Bioavailability
Topical bioavailability optimized in hypromellose ointment formulations; SAAP-148 retains activity in human plasma unlike LL-37; systemic bioavailability limited by proteolytic degradation
CAS number
Not assigned (SAAP-148 and OP-145 are novel synthetic derivatives)

Thymalin

Molecular formula
Complex mixture; active dipeptide EW: C16H19N3O5
Molecular weight
Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da
Half-life
Not precisely characterized for complex; immune effects persist weeks post-administration
Bioavailability
High via intramuscular or subcutaneous injection
CAS number
63958-90-7

Protocols

Dosing compared

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Topical

  • 0.5 mg/mL drops (about 100 microliters per application)Twice daily · 2 weeksIn a human phase 2a ear study, OP-145 drops at 0.5 mg per mL were applied to the affected ear twice daily for 2 weeks and were safe and well tolerated [4].

Thymalin

Intramuscular injection

  • 5-10 mg reconstituted in salineOnce daily · 5-10 day course, often repeated every 6 monthsReflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1].

Subcutaneous injection

  • 10 mgOnce daily · Up to 20 day course, repeated every 6 monthsSubcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1].

Applications

Best suited for

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Research into next-generation antimicrobials against multidrug-resistant infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on research into next-generation antimicrobials against multidrug-resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Topical antimicrobial development for wound infections with biofilm involvement
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on topical antimicrobial development for wound infections with biofilm involvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding vitamin D-cathelicidin innate immune axis for immune optimization
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on understanding vitamin d-cathelicidin innate immune axis for immune optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of anti-biofilm therapeutics for chronic device-related and wound infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on development of anti-biofilm therapeutics for chronic device-related and wound infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymalin

Aging Adults Seeking Immune Support
Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.
Longevity and Anti-Aging Protocols
Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.
Seasonal Illness Prevention
Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.

Safety profile

Side effects

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Common

  • Local application site irritation
  • Local inflammatory response
  • Mild wound exudate increase

Uncommon

  • Localized urticaria
  • Transient pain at injection site

Serious

  • Hemolytic activity at supratherapeutic doses

Thymalin

Common

  • No side effects in most patients
  • Mild injection site reaction

Uncommon

  • Transient low-grade fever
  • Mild flu-like symptoms
  • Temporary headache

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cathelicidin peptides (natural and synthetic) are not FDA-approved. Human data are limited: in a randomized Phase IIa trial, ear drops of the LL-37-derived peptide OP-145 were safe and well tolerated in chronic middle-ear infection [3][4]. Animal studies demonstrate broad-spectrum antimicrobial activity without systemic toxicity at therapeutic concentrations. However, concern exists regarding immunological tolerance—cathelicidin derivatives can trigger innate immune activation and inflammatory responses at high concentrations. The peptide's mechanism on immune cells is incompletely understood in humans, and effects on chronic immune signaling, tolerance development, or off-target immune activation remain uncharacterized. Bacterial resistance development to cathelicidin-based therapeutics is theoretically possible but not yet documented clinically.

Contraindications

  • Known hypersensitivity to cathelicidin-derived peptides or formulation components
  • Pregnancy and breastfeeding — insufficient reproductive safety data for synthetic derivatives
  • Active autoimmune conditions involving cathelicidin dysregulation (e.g., rosacea, psoriasis) — exogenous cathelicidin peptides may exacerbate inflammation
  • Severe systemic immunodeficiency without medical supervision — immune modulation effects may be unpredictable

Thymalin

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.

Contraindications

  • Active thymic tumors or malignancies
  • Known hypersensitivity to animal-derived peptide products
  • Pregnancy and breastfeeding (insufficient safety data)
  • Severe uncontrolled autoimmune disease without medical supervision

Decision guide

Which is right for you?

Cathelicidin (hCAP-18 / Synthetic Derivatives)

Choose Cathelicidin (hCAP-18 / Synthetic Derivatives) if…

  • Research into next-generation antimicrobials against multidrug-resistant infections
  • Topical antimicrobial development for wound infections with biofilm involvement
  • Understanding vitamin D-cathelicidin innate immune axis for immune optimization
  • Development of anti-biofilm therapeutics for chronic device-related and wound infections

Thymalin

Choose Thymalin if…

  • Immune system restoration in aging adults
  • Longevity and healthy aging support
  • Reducing infection frequency and severity
  • Multi-system health optimization